Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation.
Fluoropyrimidines radiosensitize human colon cancer cells that progress into S phase in the presence of drug (M.A. Davis, H-Y. Tang, J. Maybaum, and T.S. Lawrence. Int. J. Radiat. Biol. 67. 509-512, 1995). We hypothesized that progression occurs in cells that generate elevated levels of cyclin E-dependent kinase activity despite the presence of the fluoropyrimidine. To test this hypothesis, we treated HT29 and SW620 human colon cancer cells with fluorodeoxyuridine under conditions that produced nearly complete inhibition of thymidylate synthase but which sensitized only the HT29 cells. We found that, whereas HT29 cells progressed into S phase and demonstrated increased cyclin E-dependent kinase activity, SW620 cells arrested just past the G1-S boundary and showed no change in kinase activity. Because these cell lines have the same p53 mutation, these findings suggest that there is a p53-independent G1-S checkpoint that mediates radiosensitization produced by fluorodeoxyuridine.
Lawrence
T S
TS
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109. USA.
Davis
M A
MA
Loney
T L
TL
D002453:Cell Cycle / Q000187:drug effects; D019938:Cyclin D1; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D016213:Cyclins / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005467:Floxuridine / Q000494:pharmacology*; D006801:Humans; D015513:Oncogene Proteins / Q000378:metabolism; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D015398:Signal Transduction; D014407:Tumor Cells, Cultured / Q000166:cytology*
D016213:Cyclins; D004273:DNA, Neoplasm; D015513:Oncogene Proteins; D011838:Radiation-Sensitizing Agents; D005467:Floxuridine; D019938:Cyclin D1; D018844:Cyclin-Dependent Kinases